

7-29-02

GP/1647
\$



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket MBHB00-422)

PATENT

RECEIVED

JUL 31 2002

TECH CENTER 1600/2000

In the Application of:

Yan et al.

Before the Examiner:

R. Hayes

Group Art Unit: 1647

Serial No. 09/619, 198

Filed: July 19, 2000

For: VGF Selective Binding Agents and
Methods of Treating VGF-Related
Disorders

TRANSMITTAL LETTER

Commissioner for Patents
Washington, D.C. 20231

Sir:

In regard to the above-identified application:

1. We are transmitting herewith the attached
 - a. Response to Office Action Mailed January 29, 2002
 - b. Three Month Extension of Time
 - c. Return Receipt Postcard
2. With respect to additional fees:
 - a. An additional fee of \$ 920.00 is required.
3. Please charge our Deposit Account No. 13-2490.
4. Please charge any deficiency in the amount due, or credit any overpayment, to Deposit Account No. **13-2490**. A duplicate copy of this sheet is enclosed.
5. CERTIFICATE UNDER 37 C.F.R. 1.10: The undersigned hereby certifies that this Transmittal Letter and this paper, as described in paragraph 1 herein above, are being deposited with the United States Postal Service, as Express Mail, in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on this July 26, 2002.

July 26, 2002

By:

Kevin E. Noonan, Ph.D.
Reg No. 35,303



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. MBHB00-422)

#10A
LMS
8/6/02
RECEIVED
PATENT
JUL 31 2002

TECH CENTER 1600/2900

In the Application of:

Yan et al.

Serial No. 09/619,198

Filed: July 19, 2000

For: VGF Polypeptides and Methods of
Treating VGF-Related Disorders

Before the Examiner:
R. Hayes

Group Art Unit: 1647

RESPONSE TO OFFICE ACTION MAILED JANUARY 28, 2002

Commissioner for Patents
Washington, D.C. 20231

Sir:

Please consider the following amendments and remarks made in response to the Office Action mailed January 28, 2002.

AMENDMENTS

In the claims:

Please cancel claims 2, 3, 4, 5, 10, and 14-21 without prejudice or disclaimer.

Please amend the claims to appear as follows:

1. (Amended) An isolated polypeptide consisting of the amino acid sequence as set forth in SEQ ID

NO: 7.

(Amended) A fusion polypeptide consisting of the polypeptide of Claim 1 fused to a heterologous amino acid sequence.

(Amended) The fusion polypeptide of Claim 6 wherein the heterologous amino acid sequence is an IgG constant domain or fragment thereof.